TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T-cell therapies for cancer and other indications, announced it has advanced negotiations with both of its previously aforementioned acquisition candidates.

This past spring TCBP announced the execution of non-binding letters of intent as part of its M&A strategy aimed at expanding its therapeutic platform. The Company continues to pursue its expansion strategy via acquisition, specifically in new indications and new cell therapy modalities.

TCBP will be focusing its acquisition efforts on two main areas; Natural Kill cell technologies and CAR-related technologies. The Company intends to move forward with near-term acquisition opportunities in the NK space, reviewing several new opportunities in the allogeneic NK space as well as the CAR-NK space. This would expand the Company's efforts into autoimmune disease as well as additional opportunities in solid tumors and combination therapies using both TCB008 and an allogeneic NK cell in combination.

Additionally, the Company is pursuing new opportunities in the novel CAR space. TCB008 is an ideal candidate to be modified with new CAR technologies further to enhance its efficacy in solid tumors and other cancers. Expanding TCB008 into a CAR-modified cell increases the use case and economies of scale for the therapeutic and furthers the use of our manufacturing site, where we have room for expansion.

"TC BioPharm is encouraged by the progress that we have made during these discussions with our current acquisition targets," said Bryan Kobel, Chief Executive Officer.  "We are pursuing companies that have developed proprietary approaches to their specific areas of treatment and would significantly enhance TCBP's treatment platform while meshing with our current offerings.  Management is currently negotiating deal terms in good faith, and I believe the process is progressing to mutually beneficial outcomes.  We hope to have additional updates soon as we remain committed to establishing ourselves as a leader in novel oncology treatments."